Bristol-Myers Squibb is facing some serious near-term challenges as its top-selling drugs come under pressure, forcing it to slash its sales forecasts for the year.
Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales
NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.
A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England.<
Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin
Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.